DE1003534T1 - Reovirus zur behandlung von neoplasmen - Google Patents
Reovirus zur behandlung von neoplasmenInfo
- Publication number
- DE1003534T1 DE1003534T1 DE1003534T DE98940002T DE1003534T1 DE 1003534 T1 DE1003534 T1 DE 1003534T1 DE 1003534 T DE1003534 T DE 1003534T DE 98940002 T DE98940002 T DE 98940002T DE 1003534 T1 DE1003534 T1 DE 1003534T1
- Authority
- DE
- Germany
- Prior art keywords
- reovirus
- neoplasm
- use according
- administered
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000702263 Reovirus sp. Species 0.000 title claims abstract 45
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 25
- 208000035269 cancer or benign tumor Diseases 0.000 claims abstract 24
- 241000124008 Mammalia Species 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 27
- 230000001404 mediated effect Effects 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 4
- 241001516406 Avian orthoreovirus Species 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 206010061187 Haematopoietic neoplasm Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 241001494479 Pecora Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12261—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/911,383 US6110461A (en) | 1997-08-13 | 1997-08-13 | Reovirus for the treatment of neoplasia |
| PCT/CA1998/000774 WO1999008692A1 (en) | 1997-08-13 | 1998-08-12 | Reovirus for the treatment of neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1003534T1 true DE1003534T1 (de) | 2001-08-23 |
Family
ID=25430159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1003534T Pending DE1003534T1 (de) | 1997-08-13 | 1998-08-12 | Reovirus zur behandlung von neoplasmen |
| DE69804106T Expired - Lifetime DE69804106T2 (de) | 1997-08-13 | 1998-08-12 | Reovirus zur behandlung von neoplasmen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69804106T Expired - Lifetime DE69804106T2 (de) | 1997-08-13 | 1998-08-12 | Reovirus zur behandlung von neoplasmen |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US6110461A (https=) |
| EP (3) | EP1213023A1 (https=) |
| JP (1) | JP4291884B2 (https=) |
| AT (1) | ATE213948T1 (https=) |
| AU (1) | AU731810B2 (https=) |
| CA (1) | CA2283280C (https=) |
| DE (2) | DE1003534T1 (https=) |
| DK (1) | DK1003534T3 (https=) |
| ES (1) | ES2157870T3 (https=) |
| GR (1) | GR20010300030T1 (https=) |
| IL (1) | IL131598A (https=) |
| NZ (1) | NZ337493A (https=) |
| PT (1) | PT1003534E (https=) |
| WO (1) | WO1999008692A1 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| IL145899A0 (en) * | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
| AU2005201079C1 (en) * | 1999-04-15 | 2008-11-06 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US6586411B1 (en) | 2000-08-16 | 2003-07-01 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
| US8147822B1 (en) * | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| BR0015491A (pt) * | 1999-11-12 | 2002-10-15 | Oncolytics Biotech Inc | Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro |
| AUPQ425699A0 (en) * | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AR028039A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| US20050013803A1 (en) * | 2000-07-07 | 2005-01-20 | Benjamin Thomas L. | Diagnosing and treating cancer cells using mutant viruses |
| US20030157481A1 (en) * | 2001-12-10 | 2003-08-21 | Benjamin Thomas L. | Diagnosing and treating cancer cells using T-HR mutants and their targets |
| US20020156039A1 (en) * | 2000-07-07 | 2002-10-24 | Benjamin Thomas L. | Diagnosing and treating cancer cells using Sal2 |
| US20020147996A1 (en) * | 2000-07-07 | 2002-10-10 | Benjamin Thomas L. | Diagnosing and treating cancer cells using Sal2 |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| NZ524937A (en) | 2000-11-09 | 2004-10-29 | Oncolytics Biotech Inc | Methods for determining susceptibility of a cell to reovirus infection and for diagnosing proliferative disease treatable with reovirus |
| MXPA03004298A (es) * | 2000-11-20 | 2004-02-12 | Oncolytics Biotech Inc | Metodo para transmitir optimamente virus a masa de tumor solido. |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| JP2004519431A (ja) * | 2000-12-01 | 2004-07-02 | ユニバーシティ・オブ・オタワ | 腫瘍溶解性ウイルス |
| AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| IL157304A0 (en) | 2001-03-16 | 2004-02-19 | Oncolytics Biotech Inc | Method of extracting virus from cell culture |
| AU2002335667A1 (en) * | 2001-08-03 | 2003-02-17 | Board Of Regents, The University Of Texas System | Modified reoviral therapy |
| US20040115170A1 (en) * | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
| CA2374388C (en) * | 2002-02-28 | 2005-07-12 | Matthew C. Coffey | The use of ribozymes in the detection of adventitious agents |
| US20040005546A1 (en) * | 2002-02-28 | 2004-01-08 | Oncolytics Biotech Inc. | Use of ribozymes in the detection of adventitious agents |
| US7319001B2 (en) | 2002-03-09 | 2008-01-15 | Neurogenex Co., Ltd. | High throughput system for producing recombinant viruses using site-specific recombination |
| DE60327069D1 (de) | 2002-04-30 | 2009-05-20 | Oncolytics Biotech Inc | Verbesserte reinigungsmethode für viren |
| EP1944035A1 (en) | 2002-05-09 | 2008-07-16 | Oncolytics Biotech Inc. | Method for reducing pain using oncolytic viruses |
| JP5241059B2 (ja) * | 2002-05-09 | 2013-07-17 | オンコリティクス バイオテク，インコーポレーテッド | 腫瘍崩壊ウイルスを使用して疼痛を軽減するための方法 |
| AU2003238008A1 (en) * | 2002-06-12 | 2003-12-31 | Temple University Of The Commonwealth System Of Higher Education | Method of cell growth inhibition with agnoprotein |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| AU2002953436A0 (en) * | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US20060241178A1 (en) * | 2002-12-30 | 2006-10-26 | Immuneguard Llc | Compositions and methods for treating lung cancer |
| JP2007524363A (ja) | 2003-03-27 | 2007-08-30 | オタワ ヘルス リサーチ インスティチュート | 変異体水疱性口内炎ウイルスおよびそれらの使用 |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| WO2005002607A2 (en) * | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
| WO2005014017A1 (ja) * | 2003-08-08 | 2005-02-17 | Yuji Shino | 癌治療用医薬組成物 |
| MXPA06003318A (es) * | 2003-09-26 | 2006-06-08 | Novartis Ag | Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad. |
| US7638318B2 (en) | 2003-09-26 | 2009-12-29 | Norvartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| US20050137152A1 (en) * | 2003-12-19 | 2005-06-23 | Danny Cheung | Reovirus for the prevention of neoplasia |
| WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
| US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| US10260049B2 (en) * | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
| ES2551306T3 (es) * | 2006-02-13 | 2015-11-17 | Oncolytics Biotech Inc. | Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica |
| WO2009016433A2 (en) * | 2006-09-15 | 2009-02-05 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| SG191602A1 (en) | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| TW200909581A (en) * | 2007-05-21 | 2009-03-01 | Oncolytics Biotech Inc | Mutant reoviruses and methods of making and using |
| WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| EP2296678A4 (en) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION |
| US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| WO2012031137A2 (en) | 2010-09-02 | 2012-03-08 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| AU2013204555A1 (en) * | 2012-04-30 | 2013-11-14 | Oncolytics Biotech Inc. | Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein |
| WO2014204275A1 (ko) * | 2013-06-21 | 2014-12-24 | 한국생명공학연구원 | 리오바이러스를 유효성분으로 함유하는 혈관신생 억제용 조성물 |
| DK3068411T3 (da) | 2013-11-15 | 2020-06-22 | Oncolytics Biotech Inc | Oncolytiske vira og forøget cancerbehandlingsregimer |
| KR20230012484A (ko) * | 2020-05-20 | 2023-01-26 | 바이로큐어 주식회사 | 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4108983A (en) * | 1976-06-01 | 1978-08-22 | The Wistar Institute | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
| SE445466B (sv) * | 1977-12-01 | 1986-06-23 | Wellcome Found | Sett att foroka rotavirus in vitro |
| NL7812359A (nl) * | 1978-12-20 | 1980-06-24 | Gist Brocades Nv | Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins. |
| PT70556A (en) * | 1978-12-20 | 1980-01-01 | Gist Brocades Nv | Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines |
| US4490358A (en) * | 1982-03-01 | 1984-12-25 | President And Fellows Of Harvard College | Screening vaccines and immunization process |
| US4559229A (en) * | 1982-07-20 | 1985-12-17 | Research Foundation | Avian proventriculitis vaccine |
| JPH04503306A (ja) * | 1989-02-01 | 1992-06-18 | ザ・ジェネラル・ホスピタル・コーポレーション | 単純ヘルペスウイルス１型発現ベクター |
| WO1990011765A1 (en) * | 1989-04-11 | 1990-10-18 | Board Of Regents, The University Of Texas System | Antitumor preparation obtained following oncolysate treatment |
| CA2039921A1 (en) * | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| CA2051289C (en) * | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
| ATE178490T1 (de) * | 1993-02-16 | 1999-04-15 | Onyx Pharmaceuticals | Cytopathische viren zur therapie und prophylaxe der neoplasie |
| US5525342A (en) * | 1994-05-20 | 1996-06-11 | Akzo Nobel, N.V. | Reovirus strain 2177 and vaccine containing same |
| US5853716A (en) * | 1995-07-28 | 1998-12-29 | Yale University | Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| WO1998008541A1 (en) | 1996-08-30 | 1998-03-05 | Genzyme Corporation | Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| AR028039A1 (es) * | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
| NZ524937A (en) * | 2000-11-09 | 2004-10-29 | Oncolytics Biotech Inc | Methods for determining susceptibility of a cell to reovirus infection and for diagnosing proliferative disease treatable with reovirus |
| AR035227A1 (es) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| AU2003229180B8 (en) * | 2002-05-10 | 2009-07-02 | Oncolytics Biotech Inc. | Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| CA2825762A1 (en) * | 2005-08-31 | 2007-03-08 | Oncolytics Biotech Inc. | Method for enhancing anti-neoplastic activity of an oncolytic virus using modified dendritic cells |
| SG191602A1 (en) * | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
-
1997
- 1997-08-13 US US08/911,383 patent/US6110461A/en not_active Expired - Lifetime
-
1998
- 1998-08-12 NZ NZ337493A patent/NZ337493A/xx unknown
- 1998-08-12 EP EP01130285A patent/EP1213023A1/en not_active Withdrawn
- 1998-08-12 PT PT98940002T patent/PT1003534E/pt unknown
- 1998-08-12 AU AU88471/98A patent/AU731810B2/en not_active Expired
- 1998-08-12 DE DE1003534T patent/DE1003534T1/de active Pending
- 1998-08-12 AT AT98940002T patent/ATE213948T1/de not_active IP Right Cessation
- 1998-08-12 DE DE69804106T patent/DE69804106T2/de not_active Expired - Lifetime
- 1998-08-12 ES ES98940002T patent/ES2157870T3/es not_active Expired - Lifetime
- 1998-08-12 CA CA002283280A patent/CA2283280C/en not_active Expired - Lifetime
- 1998-08-12 DK DK98940002T patent/DK1003534T3/da active
- 1998-08-12 JP JP51259099A patent/JP4291884B2/ja not_active Expired - Lifetime
- 1998-08-12 EP EP98940002A patent/EP1003534B1/en not_active Expired - Lifetime
- 1998-08-12 US US09/485,390 patent/US6261555B1/en not_active Expired - Lifetime
- 1998-08-12 WO PCT/CA1998/000774 patent/WO1999008692A1/en not_active Ceased
- 1998-08-12 EP EP04006798A patent/EP1433483A1/en not_active Ceased
- 1998-08-12 IL IL13159898A patent/IL131598A/xx not_active IP Right Cessation
-
2000
- 2000-05-12 US US09/569,865 patent/US6344195B1/en not_active Expired - Lifetime
-
2001
- 2001-05-10 US US09/852,017 patent/US6576234B2/en not_active Expired - Lifetime
- 2001-08-31 GR GR20010300030T patent/GR20010300030T1/el unknown
- 2001-11-21 US US09/989,101 patent/US20020187125A1/en not_active Abandoned
-
2003
- 2003-04-01 US US10/403,528 patent/US7300650B2/en not_active Expired - Fee Related
-
2004
- 2004-04-30 US US10/836,857 patent/US7476382B2/en not_active Expired - Fee Related
-
2008
- 2008-10-16 US US12/252,953 patent/US20090098089A1/en not_active Abandoned
- 2008-11-03 US US12/264,072 patent/US20090110665A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1003534T1 (de) | Reovirus zur behandlung von neoplasmen | |
| Barnes et al. | Treatment of murine leukaemia with x rays and homologous bone marrow | |
| Hagan et al. | Tumor size: effect on monoclonal antibody uptake in tumor models | |
| Metcalf | Reticular tumours in mice subjected to prolonged antigenic stimulation | |
| GB1377435A (en) | Triazolobenzodiazepines | |
| Ben-Efraim et al. | Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth | |
| Lane | Some effects of cyclophosphamide (Cytoxan) on normal mice and mice with L1210 leukemia | |
| IL144043A (en) | Use of reovirus for the preparation of a pharmaceutical composition for the treatment of cellular proliferative disorders | |
| Houghton et al. | Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice | |
| Saga et al. | Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia | |
| Rowlinson-Busza et al. | Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection | |
| Kleihues et al. | Tumours of the peripheral and central nervous system induced in BD-rats by prenatal application of methyl methanesulfonate | |
| Morton et al. | Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice | |
| Burger et al. | Selective induction by N-nitrosoethylurea of oligodendrogliomas in fetal forebrain transplants | |
| Magrath et al. | Treatment of patients with high grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapy? | |
| Goldenberg | Carcinoembryonic antigen as a target cancer antigen for radiolabeled antibodies: prospects for cancer imaging and therapy | |
| Braakhuis et al. | Enhanced success rate of transplantation with human tumors in cyclophosphamide-treated nude mice | |
| Pinkerton | Where next with therapy in advanced neuroblastoma? | |
| Berdal et al. | Treatment of squamous cell carcinomas in head and neck with bleomycin and with combined bleomycin and x-rays | |
| Silverman et al. | Expression of c‐myc, c‐raf‐1, and c‐Ki‐ras in azaserine‐induced pancreatic carcinomas and growing pancreas in rats | |
| KARUBE et al. | Evaluation of 99mTc-labeled amino acids as radiopharmaceuticals. V. 99mTc complex of ethylenediamine-N, N-diacetic acid as a scintigraphic agent for tumors | |
| MAKINO et al. | Presence of albumin-positive cells in the liver of analbuminemic rats and their increase on treatment with hepatocarcinogens | |
| Manil et al. | Strong uptake of 111in‐pentetreotide by an MIBG‐negative, xenografted neuroblastoma | |
| Weston et al. | The growth and metastasis of an allografted lymphoma in normal, deprived and reconstituted mice | |
| Fukuchi et al. | Human acute myeloblastic leukemia-ascites model using the human GM-CSF-and IL-3-releasing transgenic SCID mice |